Abdominal aortic aneurysm
PILA PHARMA explores XEN-D0501 for abdominal aortic aneurysm, with preclinical data showing reduced aneurysm growth in mice.
pilapharma.comCrawled Nov 19, 2026
PILA PHARMA explores XEN-D0501 for abdominal aortic aneurysm, with preclinical data showing reduced aneurysm growth in mice.
Discover Datablocks and more insights from Pila Pharma.
PILA PHARMA researches diabetes and obesity, exploring TRPV1 inhibition and its potential role in glucose regulation and metabolic health.
PILA PHARMA is developing XEN-D0501, an oral TRPV1 inhibitor being explored as a potential treatment for the rare disease erythromelalgia.
Discover PILA video, blog and more insights from PILA PHARMA.
Discover CEO Gustav H. Gram increases holding in Pila Pharma AB and more insights from Pila Pharma.
Discover PHARMA AB - CEO Dorte X. Gram increases share holding and more insights from Pila Pharma.
The page provides insights into Pila Pharma, including updates on Dorte X. Gram’s stake increase.
Discover PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025 and more insights from Pila Pharma.
Pila Pharma announces upcoming investor events and interviews, including participation at Redeye Diabetes Day on May 6.
Pila Pharma reports low exposure to XEN-D0501 in preclinical rat obesity studies may explain lack of effect on body weight.
Discover Scientific Advisory Board and more insights from Pila Pharma.
Discover Board of Directors and more insights from Pila Pharma.
Discover Management Team and more insights from Pila Pharma.
PILA PHARMA is a clinical-stage biotech company developing XEN-D0501, an oral TRPV1 antagonist for the treatment of obesity and diabetes.
Discover Articles of association and more insights from Pila Pharma.
Discover Bolagsordning and more insights from Pila Pharma.